Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, Gennex Laboratories has informed that Board of Directors of the Company, at its meeting held today, on July 04, 2025 has considered and approved the following: Allotment of 60,00,000 Equity Shares upon Conversion of Warrants to the member of promoter group on Preferential basis. The requisite disclosures are set out in Annexure A to this letter. The Board Meeting had commenced at 02:00 pm and concluded at 02.40 pm. This intimation is also uploaded on the Company website: www.gennexlab.com.
The above information is a part of company’s filings submitted to BSE.
